Therapeutics News and Research

RSS

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

Health information technology's 11% combined annual growth rate to continue through 2013: Scientia Advisors

Health information technology (HIT) is the fastest growing segment of the $1 trillion global health care marketplace—and its “impressive” 11 per cent combined annual growth rate is likely to continue through 2013, according to a Scientia Advisors global industry review released today.

10 Nov 2009

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Particle engineering company Enavail announced today that it has obtained an exclusive license from The University of Texas at Austin for a portfolio of particle engineering technologies that will be utilized for pharmaceutical, biotechnology and nutraceutical applications.

10 Nov 2009

Dark side of compulsive eating

Researchers from Boston University School of Medicine (BUSM) have shown that intermittent access to foods rich in fat and sugar induces changes in the brain which are comparable to those observed in drug dependence. The findings, reported in the journal Proceedings of the National Academy of Sciences, may explain how abstinence from these foods contributes to relapse eating among dieters as well as related eating disorders.

10 Nov 2009

JumpStart announces investment commitment of $250,000 in Checkpoint Surgical

JumpStart Inc., the Northeast Ohio venture development organization that accelerates the progress of high growth early-stage businesses, announced a JumpStart Ventures investment commitment of $250,000 in Checkpoint Surgical, LLC. A spinout of NDI Medical, the Highland Hills, OH medical device company is developing and commercializing a surgical handheld disposable nerve stimulator.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

9 Nov 2009

Ikano Therapeutics' midazolam granted Orphan Drug designation

Ikano Therapeutics, Inc. announced today that it has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures.

9 Nov 2009

Cytori Therapeutics announces financial results for the third quarter of 2009

Cytori Therapeutics is reporting its financial results for the quarter and nine months ended September 30, 2009.

9 Nov 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases was shown to be superior to other current potential stem cell treatments.

9 Nov 2009

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

9 Nov 2009

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

Anesiva, Inc. today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC stating that the Nasdaq Hearing Panel has granted Anesiva's request for continued listing on The NASDAQ Global Market subject to the condition that Anesiva shall have completed on or before December 31, 2009, the proposed merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto.

9 Nov 2009

Financial results for the third-quarter announced by Repros Therapeutics

Repros Therapeutics today announced financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Researchers discover a fungal protein that causes disease in plants and animals

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and Montana State University have discovered a fungal protein that plays a key role in causing disease in plants and animals and which also shields the pathogen from oxidative stress.

7 Nov 2009

Halozyme Therapeutics announces results of its insulin variability study

Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.

7 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI).

6 Nov 2009

Therapeutics News and Research

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Aduro BioTech raises funds through its Series A-1 financing

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

Health information technology's 11% combined annual growth rate to continue through 2013: Scientia Advisors

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Dark side of compulsive eating

JumpStart announces investment commitment of $250,000 in Checkpoint Surgical

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Ikano Therapeutics' midazolam granted Orphan Drug designation

Cytori Therapeutics announces financial results for the third quarter of 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

Financial results for the third-quarter announced by Repros Therapeutics

Researchers discover a fungal protein that causes disease in plants and animals

Halozyme Therapeutics announces results of its insulin variability study

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News